IgAN
Advertisement
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
The Freely Filtered Filtrate discusses the top nephrology stories of 2024, including FLOW, cyberattacks, and IgAN trials.
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Zigakibart for treatment of IgA nephropathy (IgAN) was well tolerated, reduced proteinuria, and stabilized eGFR at 76 weeks.
A study examined the clinical relevance of urinary mRNA levels in patients with IgA nephropathy (IgAN).
A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.
A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.
Researchers examined the role of urinary sodium excretion and the progression of immunoglobulin A nephropathy (IgAN).
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
Jonathan Barratt discussed his research on the anti-APRIL antibody sibeprenlimab in the treatment of IgA nephropathy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.